Corcept Therapeutics (CORT) has put relacorilant back in front of regulators by resubmitting its New Drug Application to the FDA for treating Cushing’s syndrome, incorporating additional data analyses requested after earlier feedback.

Corcept Therapeutics’ latest FDA resubmission comes after a strong run in the stock, with a 30 day share price return of 32.70% and a 90 day share price return of 136.28%. The 5 year total shareholder return of 248.95% points to sustained long term gains despite recent short term pullbacks.

If relacorilant’s progress has your attention, it could be a good moment to broaden your search to other potential healthcare AI opportunities through the 38 healthcare AI stocks.

With Corcept Therapeutics now trading at $79.91 and sitting only about 4% below one intrinsic value estimate and roughly 10% below an analyst price target of $88, investors may ask whether there is still a buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 9.2% Undervalued

Corcept Therapeutics is trading at $79.91, compared with a widely followed narrative fair value of $88 that uses a detailed long term earnings model and explicit discount rate assumptions.

The publication of the CATALYST study and the resulting increased awareness and screening for hypercortisolism among physicians are expanding the potential addressable patient pool, which is expected to drive significant acceleration in revenue growth over the next several years.

Anticipated regulatory approvals for relacorilant in both hypercortisolism (end of this year) and platinum resistant ovarian cancer (next year), supported by clinically differentiated safety and efficacy data, create major new revenue and margin expansion opportunities as the company moves past single product dependence.

Curious how Corcept Therapeutics gets from today’s profit base to that higher fair value? The narrative leans on faster top line expansion, sharply higher margins, and a lower future earnings multiple than many high growth biopharma peers.

Result: Fair Value of $88 (UNDERVALUED)

However, Corcept Therapeutics’ story could look very different if Korlym faces faster generic pressure, or if relacorilant and Lifyorli approvals or uptake disappoint expectations.

Next Steps

With mixed sentiment around Corcept Therapeutics’ upside and risks, this is a moment to act quickly, review the details, and weigh the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Corcept Therapeutics?

If Corcept Therapeutics has sharpened your focus, do not stop there. Use the Simply Wall St Screener to quickly surface fresh ideas that fit your style.

• Target potential undervalued opportunities by scanning companies that combine quality fundamentals with appealing prices through the 45 high quality undervalued stocks.
• Prioritize resilience by reviewing companies that stand out in our 66 resilient stocks with low risk scores and may suit a more cautious approach to equity investing.
• Hunt for lesser known opportunities by checking the screener containing 19 high quality undiscovered gems that meet strict financial quality filters before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.